T1	Participants 68 105	patients with low ejection fractions.
T2	Participants 349 476	6797 patients with ejection fractions < or = 0.35 enrolled into the two Studies of Left Ventricular Dysfunction (SOLVD) trials.
T3	Participants 647 786	Patients with heart failure entered the treatment trial (n = 2569) and those without heart failure entered the prevention trial (n = 4228).
T4	Participants 1107 1124	362 placebo group
T5	Participants 1250 1267	595 placebo group
T6	Participants 1757 1794	patients with low ejection fractions.
